Geron Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GERN research report →
Companywww.geron.com
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
- CEO
- Harout Semerjian
- IPO
- 1996
- Employees
- 229
- HQ
- Foster City, CA, US
Price Chart
Valuation
- Market Cap
- $808.32M
- P/E
- -12.12
- P/S
- 4.12
- P/B
- 3.68
- EV/EBITDA
- -24.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 86.59%
- Op Margin
- -19.05%
- Net Margin
- -35.48%
- ROE
- -28.90%
- ROIC
- -7.77%
Growth & Income
- Revenue
- $183.88M · 138.83%
- Net Income
- $-85,782,000 · 50.86%
- EPS
- $-0.13 · 51.85%
- Op Income
- $-53,835,000
- FCF YoY
- 49.34%
Performance & Tape
- 52W High
- $2.01
- 52W Low
- $1.04
- 50D MA
- $1.55
- 200D MA
- $1.41
- Beta
- 0.68
- Avg Volume
- 18.55M
Get TickerSpark's AI analysis on GERN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 13, 26 | Williams Timothy | other | 2,500,000 |
| Apr 13, 26 | Williams Timothy | other | 0 |
| Mar 31, 26 | Spiegel Robert J. | other | 5,243 |
| Mar 25, 26 | Chinoporos Constantine | other | 270,000 |
| Mar 25, 26 | Chinoporos Constantine | other | 0 |
| Mar 25, 26 | Andrews Patricia S | other | 270,000 |
| Mar 25, 26 | Andrews Patricia S | other | 0 |
| Feb 17, 26 | Eid Joseph | other | 2,220,000 |
| Feb 17, 26 | ROBERTSON MICHELLE | other | 1,660,000 |
| Feb 18, 26 | ROBERTSON MICHELLE | other | 27,500 |
Our GERN Coverage
We haven't published any research on GERN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GERN Report →